Galera Therapeutics (GRTX) AI Stock Analysis

• Market Cap: $1.84M
• Dividend Yield: N/A
• Average Volume (3M): 63.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: 63.89%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 75,462,390
• 10 Day Avg. Volume: 87,114
• 30 Day Avg. Volume: 63,573
• PEG Ratio: <0.01
• Price to Book (P/B): -0.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.21
• Enterprise Value/Market Cap: -1.48
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.71
• Enterprise Value/Ebitda: 0.29
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.02 ▲(15.00% Upside)

The score is primarily held down by fragile financial fundamentals—no revenue, continuing losses, negative free cash flow, and especially the stressed balance sheet with negative equity and a large debt increase. Technical signals are also weak (negative MACD and sub-50 RSI), while valuation is constrained by unprofitability and lack of dividend support.

Positive Factors

Reduced Net Loss & Burn

A sharp reduction in 2024 net loss and cash burn is a durable indicator management is improving cost structure and execution. Lowerized losses extend runway, reduce near-term refinancing pressure and improve the firm's ability to fund clinical programs without immediate dilutive capital.

Improved Operating Cash Flow

Operating cash flow improvement from -$44.8M to -$12.1M signals materially better cash conversion and cost discipline. This persistent reduction in cash burn is a structural positive that can lengthen runway, lower financing needs, and provide more time to de-risk clinical assets or execute strategic options.

Asset Sale Shifts Liabilities

The sale of dismutase mimetic assets to Biossil (with upfront cash and contingent payments) materially changes Galera's balance sheet and risk profile by transferring liabilities and creating potential milestone receipts. This structural transaction can reduce solvency risk and refocus the company strategically.

Negative Factors

No Revenue / Continued Losses

The company remains pre-revenue, relying exclusively on financing to fund operations. Persistent net losses mean no internal cash generation to support R&D or commercialization, leaving long-term viability contingent on successful financing, asset monetization, or a clear path to sustainable revenue.

Highly Stressed Balance Sheet

Deeply negative equity and a step-change in leverage to ~$151M create acute solvency and refinancing risk. High leverage constrains strategic flexibility, increases creditor control risk, and raises the probability that the company must pursue dilutive or costly financing absent further asset sales or external support.

Negative Free Cash Flow / Financing Dependence

Persistent negative free cash flow (~-$12.1M in 2024) means the business cannot self-fund operations or development. Continued reliance on external capital is a structural vulnerability that can dilute shareholders, limit long-term investment, and pressure timelines for clinical and strategic milestones.

Galera Therapeutics Business Overview & Revenue Model

Company Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

How the Company Makes Money

Galera Therapeutics primarily makes money through the development and commercialization of its drug candidates. As a clinical-stage company, its revenue model is largely centered on successful clinical trials leading to regulatory approvals and subsequent commercialization of its products. Revenue streams may include milestone payments, licensing agreements, and potentially sales revenue once its therapeutics receive regulatory approval. Additionally, Galera may engage in strategic partnerships with larger pharmaceutical companies to enhance the development and distribution of its therapies, which could also contribute to its financial earnings.

Galera Therapeutics Financial Statement Overview

Summary

Financials remain very weak: no revenue, ongoing losses and negative free cash flow. The balance sheet is the largest risk with deeply negative equity and a sharp jump in debt versus a small asset base, raising solvency/financing concerns. A positive offset is the meaningful reduction in net loss and cash burn in 2024.

Income Statement

The company has generated no revenue across the provided annual periods, while losses remain material (net loss of about $19.0M in 2024 vs. ~$59.1M in 2023). Operating profitability is deeply negative (EBIT and EBITDA losses), indicating the business is still fully reliant on funding rather than commercial operations. A key positive is the sharp reduction in annual net loss in 2024, but the lack of revenue and persistent negative gross profit keep the earnings quality and sustainability weak.

Balance Sheet

The balance sheet is highly stressed: stockholders’ equity is negative in 2021–2024 (about -$143.7M in 2024), and total debt surged to ~$151.0M in 2024 from ~$1.25M in 2023. Total assets are low (~$10.1M in 2024), which limits financial flexibility and increases refinancing/solvency risk. While prior years showed stronger equity levels (2019–2020), the deterioration into deeply negative equity and the step-change in leverage are major red flags.

Cash Flow

Cash burn remains significant, but improved: operating cash flow was about -$12.1M in 2024 versus roughly -$44.8M in 2023, and free cash flow improved similarly (about -$12.1M in 2024). Free cash flow also tracked net losses closely (free cash flow-to-net income ~1x), suggesting losses are largely reflected in cash usage rather than being heavily distorted by non-cash items. The main weakness is that free cash flow is still negative, meaning continued dependence on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.83M	-3.84M	-259.00K	-114.00K	-778.00K	-368.00K
EBITDA	-9.55M	-20.16M	-70.24M	-50.61M	-72.56M	-69.01M
Net Income	-8.99M	-18.96M	-59.08M	-62.22M	-80.53M	-74.22M
Balance Sheet
Total Assets	5.00M	10.10M	26.14M	44.04M	83.31M	84.10M
Cash, Cash Equivalents and Short-Term Investments	4.47M	8.29M	18.26M	31.60M	71.22M	72.78M
Total Debt	0.00	151.05M	1.25M	44.00K	302.00K	534.00K
Total Liabilities	151.65M	153.77M	157.33M	153.22M	141.31M	77.98M
Stockholders Equity	-146.65M	-143.67M	-131.19M	-109.18M	-58.00M	6.12M
Cash Flow
Free Cash Flow	-2.34M	-12.14M	-44.91M	-43.45M	-68.24M	-59.99M
Operating Cash Flow	-2.34M	-12.14M	-44.85M	-43.43M	-67.96M	-59.54M
Investing Cash Flow	-50.00K	-46.00K	27.29M	23.99M	5.24M	36.55M
Financing Cash Flow	2.86M	2.22M	31.50M	3.89M	66.71M	20.51M

Galera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTX, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRTX.

Galera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EVAX	58 Neutral	$28.74M	-0.49	―	―	4455.07%	77.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	43 Neutral	$737.84K	-0.07	―	―	178.82%	-4121.10%
GRTX	41 Neutral	$1.84M	-0.18	13.71%	―	―	63.89%
ONCO	33 Underperform	$2.53M	>-0.01	-263.57%	―	-34.58%	96.41%

Galera Therapeutics Corporate Events

Galera Therapeutics Sells Assets to Biossil Inc.

On October 15, 2025, Galera Therapeutics entered into an Asset Purchase and Sale Agreement with Biossil Inc., selling its dismutase mimetic assets, including avasopasem and rucosopasem. This transaction, completed by October 21, 2025, involved Biossil assuming liabilities related to these assets, including obligations under the Blackstone Agreement, thus shifting financial responsibilities from Galera to Biossil.

Galera Therapeutics Sells Assets to Biossil Inc.

On October 15, 2025, Galera Therapeutics, Inc. and its subsidiary entered into an agreement with Biossil Inc. to sell their assets related to avasopasem and rucosopasem. The transaction includes an upfront payment of $3.5 million and potential future payments up to $105 million, impacting the company’s focus and financial strategy.